This Robert H. Allen, MD Memorial Hematology Symposia presentation by Daniel Sherbenou, MD, PhD, will discuss how Myeloma Drug Sensitivity Testing and looking at biomarkers of disease response to new and emerging anti-myeloma therapies in bone marrow and peripheral blood may contribute to our understanding of patients' disease and optimize their treatment.
Questions may be submitted using the Q/A feature in Zoom during the Q&A portion of the presentation. Due to time limitations, some submitted questions may not be addressed.
To claim CE credit, attendees should complete the appropriate evaluation provided via links in the chat at the end of each presentation.
Recordings of this presentation will be made available to attendees.
We look forward to seeing you there!